Last Updated on October 22, 2025 by The Health Master
Pharma and Medical Device
Haryana has identified its next growth area becoming a global hub for pharma and medical device manufacturing.
The state government has instituted a new policy that aims to create a comprehensive, sustainable ecosystem for the sector generating an expected investment of ₹5,000 crore Yes, that’s a billion with the following benefits.
Policy Focused on Elevating the Manufacturer’s Experience
The Haryana Pharma and Medical Device Manufacturing Policy is filled with fiscal incentives to support the manufacturer experience straight from government to investment.
The following gives a comprehensive overview of what’s on the table for potential manufacturers:
Capital Expenditure Support:
From a government’s perspective, billion/₹ crores projects are not uncommon, as they stem from aspirations of great growth.
To offset new development costs for units, the policy allows for capital expenditure support for projects up to ₹200 crore.
The allowance lowers the threshold burden of startup capital at such high prices.
Operational Expenditure Support:
The government doesn’t stop financing major projects; it continues through their operation.
Once established, units are eligible for operational expenditure support up to ₹20 crore.
This helps facilitate units in their day-to-day endeavors once they’re part of the fabric of Haryana.
Prototype Funding for Startups:
For those innovative entrepreneurs out there, special considerations can help those newcomers get off the ground.
Eligible startups those that are Haryana based and working within the pharma or medical device sector can get 50% reimbursement on expenses incurred when creating a prototype product with an annual cap of ₹10 lakh.
This provides entrepreneurs the assistance needed to take their bright ideas and make them functional realities.
Foundational Considerations for a Sustainable Future
While financial incentives are in play, the government has other goals in mind to ensure a sustainable future for the state and country:
Infrastructure and R&D:
For real estate developers looking to build new industrial opportunities, there are incentives for creating specific pharma and medical device clusters and parks.
These areas will house shared incubation centers and research and development facilities to promote communal efforts toward individual goals.
Reduced Import Reliance:
Another goal is to ensure, at some point, that Haryana does not have to import pharma and medical device, as it will produce enough quality goods on its own.
Encouraging domestic manufacturing efforts along the entire healthcare value chain will allow Haryana to have its inventory of equipment and medicines while promoting national support for quality goods.
Export Opportunities:
While companies may want to focus solely on state-side efforts, the policy helps businesses gain international certifications and access global markets.
Therefore, if companies would like to export their products, assistance is available.
Skilled Development:
Ultimately, the policy aims to create a sustainable ecosystem through skill development.
Therefore, a trained workforce will ensure that educational institutions develop talent for years to come.
Q: What is the key objective of the new Pharma and Medical Device Manufacturing Policy?
The new Pharma and Medical Device Manufacturing Policy aims to make Haryana a go-to destination for pharma and medical device manufacturing within India while promoting local manufacturing efforts in-state with expected investments upwards of ₹5,000 crore.
Q: What types of R&D incentives are offered?
There are fiscal incentives supporting R&D and incubation infrastructure development, as well as dedicated pharma and medical device clusters encouraged.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
FDA Haryana secures Convictions in Landmark Drug Cases
A New Era for Haryana’s Pharma Industry: Lalit Kr Goel
Haryana: Crackdown on illegal sale of MTP Kit: FIR Lodged
Illegal Clinic Busted in Sonepat for Selling MTP Kit: Haryana
CDSCO Redefines Cocrystals as ‘New Drugs’
NPPA fixed retail price of 9 formulations: September 2025
USFDA issued Form 483 to Reddy’s with 5 observations: Hyderabad
USFDA approval granted for blood clotting drug: Alembic
USFDA puts import Alert on Sun Pharma: Halol
Indian Drug Regulation Goes 97% Digital: CDSCO
5 Northern State SDCs Unite Against Counterfeit Drugs
USFDA issued Form 483 to Biocon with 5 observations
